This week, Colorado Governor Jared Polis, D, signed the nation’s first bill that will cap insulin co-pays at $100 per month for people with health insurance.
This week, Colorado Governor Jared Polis, D, signed the nation’s first bill that will cap insulin co-pays at $100 per month for people with health insurance. The bill also authorizes the state’s attorney general (AG) to investigate the rising price of insulin.
The bill was sponsored by State Representative Dylan Roberts, D, whose brother died at 22 of type 1 diabetes complications in August 2016.
The cap will go into effect on January 1, 2020. Insurance companies will pay anything above $100, regardless of how much insulin is used.
The attorney general may begin investigating insulin prices immediately. The law also instructs the attorney general to make recommendations to the state legislature.
In an email to The Center for Biosimilars®, Roberts said the law applies only to those with private insurance.
“For those without insurance, that is still a huge problem that I will continue to work on. I also sponsored 2 successful bills this year to increase access to health insurance,” he said, referring to a bill that creates a public insurance option and another that allows the creation of health insurance cooperatives. The majority of Coloradans are insured, but 4% are not, he said.
“The second part of the insulin bill that was signed into law directs the attorney general to investigate pricing and make recommendations on what we should do next to get at the underlying problem of insulin prices, so I am looking forward to continue working on this issue with the AG and others,” he said.
In a statement, the American Diabetes Association said more than 400,000 people in the state have diabetes. “With the prices of insulin nearly tripling between 2002 and 2013, people with diabetes often face financial hardships affording their insulin,” said LaShawn McIver, MD, a senior vice president.
The ADA and others have been testifying at numerous hearings in Congress over the past few months about the rising cost of insulin.
In response, companies have started their own programs to cut insulin prices or limit co-pays, including Cigna and its pharmacy benefits manager Express Scripts; Eli Lilly, meanwhile, launched its lower-cost insulin lispro injection this week.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.